Company Reports

Crispr Therapeutics is an emerging gene editing company focused on the development of Crispr/Cas9-based therapeutics. The company's proprietary platform specializes in clustered regularly interspaced short palindromic repeats (Crispr)/Cas9, which precisely cuts DNA to disrupt, delete, correct, and insert genes to treat genetically defined diseases. Crispr's emerging technology has led to a new class of therapies, which are well-suited for targeting rare diseases or other disorders that are caused by genetic mutations.

Crispr Therapeutics and Vertex's gene therapy, Casgevy, continued to gain traction in the second quarter, generating $76 million in revenue. Crispr posted a net loss of $0.94 per share for the quarter, an improvement from a loss of $2.40 in the prior-year period. Shares jumped 7% on Aug. 4.

Crispr and Vertex's gene therapy Casgevy continues to gain traction, generating $43 million in first-quarter revenue. Crispr reported a net loss of $123 million and $2.44 billion in cash and marketable securities, up from $1.98 billion at year-end.

Crispr Therapeutics is an emerging gene editing company focused on the development of Crispr/Cas9-based therapeutics. The company's proprietary platform specializes in clustered regularly interspaced short palindromic repeats (Crispr)/Cas9, which precisely cuts DNA to disrupt, delete, correct, and insert genes to treat genetically defined diseases. Crispr's emerging technology has led to a new class of therapies, which are well-suited for targeting rare diseases or other disorders that are caused by genetic mutations.

Crispr's gene therapy Casgevy, in partnership with Vertex Pharmaceuticals, is gaining traction, generating $54 million in fourth-quarter revenue and $116 million for the year. Crispr's early-stage pipeline is also making progress, but the firm ended the year with a net loss of $581 million.

Crispr Therapeutics made progress in the third quarter on its commercialization efforts for gene therapy Casgevy and early-stage pipeline candidates, notably CTX310 for high triglycerides and LDL cholesterol. It posted a net loss of $106 million and $1.9 billion in cash and marketable securities.

Crispr Therapeutics reported pipeline progress in the second-quarter and it has opened 75 global treatment centers for its gene therapy, Casgevy. Its net loss widened to $2.40 per share from $1.49 in the prior-year period, mainly due to a $96.3 million payment related to Sirius Therapeutics.

No-moat Crispr Therapeutics announced progress across its early-stage portfolio at an investor conference. Clinical trials are ongoing for Crispr’s next-generation CAR-T product candidates, CTX112 and CTX131, targeting CD19 and CD70, respectively, across multiple indications. Positive data for CTX112 in a phase 1/2 trial demonstrates strong efficacy comparable with autologous therapies, a tolerable safety profile, and robust cell expansion. We assign this candidate a 20% probability of approval in our base case, and we anticipate it could reach the market as early as 2028.

Crispr Therapeutics is an emerging gene editing company focused on the development of Crispr/Cas9-based therapeutics. The company's proprietary platform specializes in clustered regularly interspaced short palindromic repeats (Crispr)/Cas9, which precisely cuts DNA to disrupt, delete, correct, and insert genes to treat genetically defined diseases. Crispr's emerging technology has led to a new class of therapies, which are well suited for targeting rare diseases or other disorders that are caused by genetic mutations.

Crispr Therapeutics reported end-2024 results in line with our expectations and Crispr’s diverse pipeline is continuing to make progress. We maintain our fair value estimate of $106 per share and view shares as very undervalued. Due to Crispr’s emerging stage, we do not assign it an economic moat. Crispr provides long-term investors who possess a very high degree of risk tolerance with pure-play exposure to novel gene editing technology across a variety of diseases, including solid tumors, cardiovascular diseases, and Type 1 diabetes. We assign probabilities of approval between 0% and 20% to these candidates due to their early stages.

Crispr Therapeutics continues to make progress across its diverse pipeline. Additionally, Crispr and its partner, narrow-moat Vertex Pharmaceuticals, are rolling out commercialization efforts globally for their gene therapy, Casgevy, for the treatment of both sickle cell disease and transfusion-dependent beta thalassemia. We revisited our estimates for Casgevy and lower our fair value estimate to $106 per share from $119 due to a slow sales ramp, which requires a lengthy process that can take nearly a year to administer this highly complex gene therapy. Nevertheless, we think Casgevy could hold strong pricing power and become a blockbuster drug during our 10-year forecast period. We view the stock as very undervalued, currently trading in 5-star territory.

Crispr Therapeutics is a clinical-stage gene editing company focused on the development of Crispr/Cas9-based therapeutics. The company's proprietary platform specializes in clustered regularly interspaced short palindromic repeats (Crispr)/Cas9, which precisely cuts DNA to disrupt, delete, correct, and insert genes to treat genetically defined diseases. Crispr's emerging technology has led to a new class of therapies, which are well suited for targeting rare diseases or other disorders that are caused by genetic mutations.

Crispr Therapeutics’ second-quarter results are tracking our expectations, and its early-stage pipeline candidates are advancing in clinical trials. We continue to expect 2024 will be a pivotal year as Crispr rolls out commercialization efforts globally for its recently approved gene therapy, Casgevy, for the treatment of both sickle cell disease and transfusion-dependent beta thalassemia. We think Casgevy could hold strong pricing power and eventually become a blockbuster drug, generating over $1 billion annually in sales. We like that Crispr and Vertex are focused on opening approved treatment centers for Casgevy, and it has 35 centers active out of its plan to open around 75 across the globe. We maintain our positive long-term outlook and $119 fair value estimate. We view the stock as very undervalued, currently trading in 5-star territory. Crispr provides long-term investors who possess a high degree of risk tolerance with pure-play exposure to novel gene editing technology.

Crispr Therapeutics’ first-quarter results align with our expectations, and its early-stage pipeline candidates are advancing in clinical trials. We continue to expect 2024 will be a pivotal year as Crispr rolls out global commercialization efforts for its recently approved gene therapy, Casgevy, for the treatment of both sickle cell disease and transfusion-dependent beta thalassemia. We think Casgevy could hold strong pricing power and become a blockbuster drug, generating over $1 billion in revenue by 2026 for Crispr, pending a successful commercial launch.

Crispr Therapeutics is a clinical-stage gene editing company focused on the development of Crispr/Cas9-based therapeutics. The company's proprietary platform specializes in clustered regularly interspaced short palindromic repeats (Crispr)/Cas9, which precisely cuts DNA to disrupt, delete, correct, and insert genes to treat genetically defined diseases. Crispr's emerging technology has led to a new class of therapies, which are well suited for targeting rare diseases or other disorders that are caused by genetic mutations.

Crispr Therapeutics has achieved many recent milestones, most notably the approval of Casgevy for the treatment of patients with sickle cell disease or transfusion-dependent beta thalassemia. Clinical trials are advancing for its early-stage pipeline with candidates evaluating the treatment of Type 1 diabetes, liquid and solid tumors, and cardiovascular diseases. We maintain our positive long-term outlook and $119 fair value estimate. We view the stock as undervalued, trading in 4-star territory about 30% below our fair value estimate. Crispr provides long-term investors who possess a high degree of risk tolerance with pure-play exposure to novel gene editing technology.

Crispr Therapeutics has achieved many recent milestones, most notably the approval of Casgevy for the treatment of patients with either sickle cell disease or transfusion-dependent beta thalassemia. Additionally, clinical trials are advancing for its early-stage pipeline with candidates evaluating the treatment of Type 1 Diabetes, liquid and solid tumors, and cardiovascular diseases. We maintain our positive long-term outlook and fair value estimate of $119 per share. We view the stock as undervalued, currently trading in 4-star territory about 30% below our fair value estimate. Crispr provides long-term investors who possess a high degree of risk tolerance with pure-play exposure to novel gene editing technology.

CRISPR Therapeutics reported third-quarter results in line with our expectations, and its pipeline candidates are continuing to make progress. We maintain our positive outlook and fair value estimate of $119 per share. We view the stock as very undervalued, currently trading about 53% below our fair value estimate.

CRISPR Therapeutics reported second-quarter results in line with our expectations, and its pipeline candidates are continuing to make progress. Collaboration revenue totaled $70 million, which was largely attributable to a research milestone achieved in connection with CRISPR’s agreement with narrow-moat Vertex Pharmaceuticals. We maintain our positive outlook and fair value estimate of $119 per share. We view the stock as very undervalued, currently trading in 5-star territory about 55% below our fair value estimate.

CRISPR Therapeutics reported first-quarter results in line with our expectations, and its pipeline candidates are continuing to progress in development. We maintain our positive outlook and fair value estimate of $119 per share, and we view the stock as very undervalued. Collaboration revenue totaled $100 million in the quarter, which was largely attributable to an upfront payment from narrow-moat Vertex Pharmaceuticals. CRISPR ended the quarter in a healthy financial position with about $1.89 billion in cash, which will help fund its research and development expenses as it develops its pipeline candidates. Investors reacted favorably, sending the stock up 13%.